Oliver Senn

Dr. Oliver Senn

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASAndreas L. Serra
Andreas L. Serra
DPDiane Poster
Diane Poster
AKAndreas D. Kistler
Andreas D. Kistler
FKFabienne Krauer
Fabienne Krauer
SRShagun Raina
Shagun Raina
RWRudolf P. Wüthrich
Rudolf P. Wüthrich
In autosomal dominant polycystic kidney disease (ADPKD), aberrant activation of the mammalian target of rapamycin (mTOR) pathway is associated with progressive kidney enlargement. The drug sirolimus suppresses mTOR signaling.

15 November 2011 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MKMalcolm Kohler
Malcolm Kohler
ASAnne-Christin Stoewhas
Anne-Christin Stoewhas
LALisa Ayers
Lisa Ayers
OSOliver Senn
Oliver Senn
KBKonrad E. Bloch
Konrad E. Bloch
JSJohn R. Stradling
John R. Stradling
Rationale: To establish a new approach to investigate the physiological effects of obstructive sleep apnea (OSA), and to evaluate novel treatments, during a period of continuous positive airway pressure (CPAP) withdrawal. Objectives: To determine the effects of CPAP withdrawal. Methods: Forty-one patients with OSA and receiving CPAP were randomized to either CPAP withdrawal (subtherapeutic CPAP), or continued CPAP, for 2 weeks. Polysomnography, sleepiness, psychomotor performance, endothelial function, blood pressure (BP), heart rate (HR), urinary catecholamines, blood markers of systemic inflammation, and metabolism were assessed. Measurements and Main Results: CPAP withdrawal led to a recurrence of OSA within a few days and a return of subjective sleepiness, but was not associated with significant deterioration of psychomotor performance within 2 weeks. Endothelial function, assessed by flow-mediated dilatation, decreased significantly in the CPAP withdrawal group compared with therapeutic CPAP (mean difference in change, –3.2%; 95% confidence interval [CI], –4.5, –1.9%; P < 0.001). Compared with continuing CPAP, 2 weeks of CPAP withdrawal was associated with a significant increase in morning systolic BP (mean difference in change, +8.5 mm Hg; 95% CI, +1.7, +15.3 mm Hg; P = 0.016), morning diastolic BP (mean difference in change, +6.9 mm Hg; 95% CI, +1.9, +11.9 mm Hg; P = 0.008), and morning HR (mean difference in change, +6.3 bpm, 95% CI, +0.4, +12.2 bpm; P = 0.035). CPAP withdrawal was associated with an increase in urinary catecholamines but did not lead to an increase in markers of systemic inflammation, insulin resistance, or blood lipids. Conclusions: CPAP withdrawal usually leads to a rapid recurrence of OSA, a return of subjective sleepiness, and is associated with impaired endothelial function, increased urinary catecholamines, blood pressure, and heart rate. Thus the proposed study model appears to be suitable to evaluate physiological and therapeutic effects in OSA. Clinical trial registered with www.controlled-trials.com (ISRCTN 93153804).

1 November 2007 in Chest
Verified
Journal Article
Closed access
TBThomas Brack
Thomas Brack
ITIrene Thüer
Irene Thüer
CCChristian F. Clarenbach
Christian F. Clarenbach
OSOliver Senn
Oliver Senn
GNGeorg Noll
Georg Noll
KBKonrad E. Bloch
Konrad E. Bloch

1 January 2009 in Kidney International
Verified
Journal Article
Closed access
AKAndreas D. Kistler
Andreas D. Kistler
DPDiane Poster
Diane Poster
FKFabienne Krauer
Fabienne Krauer
DWDominik Weishaupt
Dominik Weishaupt
SRShagun Raina
Shagun Raina
ASAndreas L. Serra
Andreas L. Serra

1 September 2005 in Chest
Verified
Journal Article
Closed access
PDF file
CCChristian F. Clarenbach
Christian F. Clarenbach
OSOliver Senn
Oliver Senn
TBThomas Brack
Thomas Brack
MKMalcolm Kohler
Malcolm Kohler
KBKonrad E. Bloch
Konrad E. Bloch

19 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OROliver Reich
Oliver Reich
TRThomas Rosemann
Thomas Rosemann
RRRoland Rapold
Roland Rapold
EBEva Blozik
Eva Blozik
OSOliver Senn
Oliver Senn
To describe the prevalence and determinants of potentially inappropriate medication (PIM) use and association with hospitalizations in an elderly managed care population in Switzerland. Using health care claims data of four health insurers for a sample of managed care patients 65 years of age and older to compare persons on PIM with persons not on PIM. Beers' 2012 and PRISCUS criteria were used to determine the potential inappropriateness of prescribed medications. The sample included 16′490 elderly patients on PIM and 33′178 patients not on PIM in the time period of January 1, 2008 through December 31, 2012. Prevalence estimates are standardized to the population of Switzerland. Associations between PIM and hospitalizations were examined by multivariate Cox regression analyses controlling for possible confounding variables. The estimated prevalence of PIM use in our managed care sample was 22.5%. Logistic regression analysis showed that number of different medications used in the previous year, total costs in the previous year and hospitalization in the previous year all significantly increased the likelihood of receiving PIM. Multiple Cox regression analysis revealed that those on cumulative levels of PIM use acted significantly as a factor related to greater hospitalization rates: the adjusted HR was 1.13 (95% CI 1.07–1.19) for 1 PIM, 1.27 (95% CI 1.19–1.35) for 2 PIM, 1.35 (95% CI 1.22–1.50) for 3 PIM, and 1.63 (95% CI 1.40–1.90) for more than 3 PIM compared to no PIM use. The prevalence of PIM in managed care health plans are widely found but seem to be much lower than rates of non-managed care plans. Furthermore, our study revealed a significant association with adverse outcomes in terms of hospitalizations. These findings stress the need for further development of interventions to decrease drug-related problems and manage patients with multiple chronic conditions.